The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by p...
Saved in:
| Published in: | The Lancet infectious diseases Vol. 18; no. 10; pp. e295 - e311 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Ltd
01.10.2018
Elsevier B.V Elsevier Limited |
| Subjects: | |
| ISSN: | 1473-3099, 1474-4457, 1474-4457 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide. |
|---|---|
| AbstractList | The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide. Summary The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide. The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide. |
| Audience | Academic |
| Author | Greenough, Anne Knezevic, Ivana Langedijk, Annefleur C McLellan, Jason S Stein, Renato T Nunes, Marta C Englund, Janet A Graham, Barney S Nair, Harish Papadopoulos, Nikolaos G Higgins, Deborah Powell, Mair Chu, Helen Y Falsey, Ann R Bont, Louis J Vekemans, Johan Satav, Ashish Karron, Ruth A Buchholz, Ursula J Piedra, Pedro A Baraldi, Eugenio Simões, Eric AF Walsh, Edward E Mazur, Natalie I Polack, Fernando P Kragten-Tabatabaie, Leyla Horsley, Nicole Mejias, Asuncion Melero, José A Ramilo, Octavio Openshaw, Peter J |
| Author_xml | – sequence: 1 givenname: Natalie I surname: Mazur fullname: Mazur, Natalie I organization: Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands – sequence: 2 givenname: Deborah surname: Higgins fullname: Higgins, Deborah organization: Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA – sequence: 3 givenname: Marta C surname: Nunes fullname: Nunes, Marta C organization: Medical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa – sequence: 4 givenname: José A surname: Melero fullname: Melero, José A organization: Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III Majadahonda, Madrid, Spain – sequence: 5 givenname: Annefleur C surname: Langedijk fullname: Langedijk, Annefleur C organization: Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands – sequence: 6 givenname: Nicole surname: Horsley fullname: Horsley, Nicole organization: Department of Biology, University of Washington, Seattle, WA, USA – sequence: 7 givenname: Ursula J surname: Buchholz fullname: Buchholz, Ursula J organization: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA – sequence: 8 givenname: Peter J surname: Openshaw fullname: Openshaw, Peter J organization: National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, UK – sequence: 9 givenname: Jason S surname: McLellan fullname: McLellan, Jason S organization: Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA – sequence: 10 givenname: Janet A surname: Englund fullname: Englund, Janet A organization: Department of Pediatrics, University of Washington, Seattle, WA, USA – sequence: 11 givenname: Asuncion surname: Mejias fullname: Mejias, Asuncion organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 12 givenname: Ruth A surname: Karron fullname: Karron, Ruth A organization: Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA – sequence: 13 givenname: Eric AF surname: Simões fullname: Simões, Eric AF organization: Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA – sequence: 14 givenname: Ivana surname: Knezevic fullname: Knezevic, Ivana organization: Norms and Standards for Biologicals, Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland – sequence: 15 givenname: Octavio surname: Ramilo fullname: Ramilo, Octavio organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 16 givenname: Pedro A surname: Piedra fullname: Piedra, Pedro A organization: Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA – sequence: 17 givenname: Helen Y surname: Chu fullname: Chu, Helen Y organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 18 givenname: Ann R surname: Falsey fullname: Falsey, Ann R organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 19 givenname: Harish surname: Nair fullname: Nair, Harish organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 20 givenname: Leyla surname: Kragten-Tabatabaie fullname: Kragten-Tabatabaie, Leyla organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 21 givenname: Anne surname: Greenough fullname: Greenough, Anne organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 22 givenname: Eugenio surname: Baraldi fullname: Baraldi, Eugenio organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 23 givenname: Nikolaos G surname: Papadopoulos fullname: Papadopoulos, Nikolaos G organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 24 givenname: Johan surname: Vekemans fullname: Vekemans, Johan organization: Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland – sequence: 25 givenname: Fernando P surname: Polack fullname: Polack, Fernando P organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 26 givenname: Mair surname: Powell fullname: Powell, Mair organization: Licensing Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK – sequence: 27 givenname: Ashish surname: Satav fullname: Satav, Ashish organization: Mahatma Gandhi Tribal Hospital, Karmagram, Utavali, Tahsil, Dharni, India – sequence: 28 givenname: Edward E surname: Walsh fullname: Walsh, Edward E organization: Department of Medicine, University of Rochester and Rochester General Hospital, Rochester, NY, USA – sequence: 29 givenname: Renato T surname: Stein fullname: Stein, Renato T organization: Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands – sequence: 30 givenname: Barney S surname: Graham fullname: Graham, Barney S organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA – sequence: 31 givenname: Louis J surname: Bont fullname: Bont, Louis J email: l.bont@umcutrecht.nl organization: Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29914800$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUuLFDEUhYOMOA_9CUpAkHFRmmdXRZFhGHzBgAvHdbidutVmrE61Saqx_v2ku0YXvRmzSXL5zuFwzyk5CkNAQp5z9oYzvnj7nataVpIZc86b15IJIyr9iJyUsaqU0vXR_j0jx-Q0pVvGeM2ZekKOhTFcNYydkO7mJ9KIaeMj5CFONE3BTdlDT7c-joluwTkfkPYQ2uRgg-9ojykNIdEuDmuai34VYYsTxJYWiG7K2CcfVtSVr28hY3pKHnfQJ3x2f5-RH58-3lx9qa6_ff56dXldOW14rgw3uhWsMwq07EpytzCILXYgmrZGQOA1LFgnJeucUZ3UjUKJZtlwYYAv5Rk5n31LiN8jpmxLFId9SY_DmKxguuZS6YYX9OUBejuMMZR0VnCtxP4U6tVMraBH64MbQsY_eQVjStZear1gQjRyB764txuXa2ztJvo1xMn-XXUB9Ay4OKQUsfuHcGZ3ldp9pXbXl-WN3VdqddG9P9A5nyH7EiSC7x9UX8xqLFvfeow2OY_BYesjumzbwT_o8OHAwfU-eAf9L5z-Q38HWlrNkA |
| CitedBy_id | crossref_primary_10_1080_14712598_2020_1753696 crossref_primary_10_3390_biologics4010002 crossref_primary_10_1093_cid_ciaa951 crossref_primary_10_1097_INF_0000000000003640 crossref_primary_10_1128_JVI_00485_21 crossref_primary_10_2196_38026 crossref_primary_10_3389_fmicb_2021_671852 crossref_primary_10_1128_JVI_01512_20 crossref_primary_10_3390_pathogens9020135 crossref_primary_10_1016_j_clim_2019_108324 crossref_primary_10_1038_s41467_025_62358_w crossref_primary_10_1128_JVI_01879_19 crossref_primary_10_3389_fmicb_2024_1457703 crossref_primary_10_1155_2021_9940010 crossref_primary_10_3390_vaccines13020097 crossref_primary_10_1093_cid_ciaa944 crossref_primary_10_3390_v15051067 crossref_primary_10_12688_wellcomeopenres_15268_2 crossref_primary_10_12688_wellcomeopenres_15268_1 crossref_primary_10_1016_j_vaccine_2019_06_022 crossref_primary_10_3389_fimmu_2025_1574568 crossref_primary_10_1016_j_ogc_2023_02_011 crossref_primary_10_3389_fimmu_2021_681449 crossref_primary_10_1093_cid_ciab595 crossref_primary_10_1186_s12879_022_07289_3 crossref_primary_10_1093_infdis_jiac407 crossref_primary_10_1093_infdis_jiab315 crossref_primary_10_3389_fimmu_2019_01154 crossref_primary_10_1371_journal_pone_0234235 crossref_primary_10_1016_j_immuni_2019_08_007 crossref_primary_10_1099_jgv_0_001471 crossref_primary_10_3389_fimmu_2019_02806 crossref_primary_10_1080_1744666X_2019_1541737 crossref_primary_10_3390_v12060637 crossref_primary_10_1126_scitranslmed_abo5032 crossref_primary_10_1186_s12979_021_00249_6 crossref_primary_10_3390_pathogens8020067 crossref_primary_10_1097_INF_0000000000002650 crossref_primary_10_1126_sciimmunol_aba6466 crossref_primary_10_1038_s41541_024_01059_9 crossref_primary_10_3389_fimmu_2022_1081107 crossref_primary_10_1002_rmv_2284 crossref_primary_10_1093_infdis_jiaa310 crossref_primary_10_1016_j_heares_2019_07_003 crossref_primary_10_3390_pharmaceutics15030782 crossref_primary_10_1177_17151635231210879 crossref_primary_10_1080_23744235_2024_2402914 crossref_primary_10_1016_j_vaccine_2022_06_034 crossref_primary_10_1007_s12016_022_08948_8 crossref_primary_10_1126_science_aav9033 crossref_primary_10_1080_17476348_2019_1554439 crossref_primary_10_1016_j_jcv_2022_105223 crossref_primary_10_1093_infdis_jiz395 crossref_primary_10_1186_s12887_020_02390_5 crossref_primary_10_1016_j_antiviral_2019_05_001 crossref_primary_10_1038_s41573_021_00283_5 crossref_primary_10_1097_INF_0000000000002666 crossref_primary_10_1016_j_eimce_2024_01_012 crossref_primary_10_1016_j_vaccine_2021_05_076 crossref_primary_10_1111_irv_12914 crossref_primary_10_1007_s11739_023_03438_x crossref_primary_10_1371_journal_ppat_1007944 crossref_primary_10_1007_s40273_022_01142_w crossref_primary_10_1038_s41541_021_00347_y crossref_primary_10_1080_14787210_2019_1581062 crossref_primary_10_1093_jpids_piaa094 crossref_primary_10_3390_vaccines7030107 crossref_primary_10_1016_j_vaccine_2019_07_089 crossref_primary_10_7189_jogh_09_010433 crossref_primary_10_1038_s41598_022_07346_6 crossref_primary_10_1186_s12879_023_08100_7 crossref_primary_10_1186_s13643_020_01527_y crossref_primary_10_1371_journal_pone_0229660 crossref_primary_10_1093_infdis_jiad271 crossref_primary_10_3390_vaccines13010052 crossref_primary_10_1111_bph_15318 crossref_primary_10_1016_j_idc_2023_03_004 crossref_primary_10_1542_peds_2019_3611 crossref_primary_10_1016_j_heliyon_2023_e14422 crossref_primary_10_1177_2040206620947303 crossref_primary_10_1016_j_eimce_2020_01_003 crossref_primary_10_3390_pathogens12101259 crossref_primary_10_1186_s12916_020_01802_8 crossref_primary_10_3389_fimmu_2022_863149 crossref_primary_10_1038_s44298_024_00075_9 crossref_primary_10_1056_NEJMoa2209604 crossref_primary_10_1080_14760584_2019_1657013 crossref_primary_10_3390_vaccines8040716 crossref_primary_10_3389_fimmu_2019_01366 crossref_primary_10_3389_fimmu_2019_01006 crossref_primary_10_3389_fmolb_2024_1342179 crossref_primary_10_1016_j_vacune_2022_10_007 crossref_primary_10_1016_j_jbiotec_2020_10_014 crossref_primary_10_1080_17460441_2022_2123468 crossref_primary_10_1165_rcmb_2020_0025LE crossref_primary_10_1183_13993003_03766_2020 crossref_primary_10_1542_gr_44_5_51 crossref_primary_10_3390_vaccines12010030 crossref_primary_10_1080_13543784_2022_2020248 crossref_primary_10_1056_NEJMoa2213836 crossref_primary_10_1038_s41467_025_56302_1 crossref_primary_10_1097_INF_0000000000002404 crossref_primary_10_1155_2024_8734457 crossref_primary_10_1126_scitranslmed_ade0424 crossref_primary_10_1016_j_cytogfr_2022_10_001 crossref_primary_10_1016_j_ymthe_2024_02_011 crossref_primary_10_1016_S1473_3099_22_00291_2 crossref_primary_10_1183_13993003_00651_2021 crossref_primary_10_1186_s12951_025_03560_2 crossref_primary_10_1186_s12955_023_02174_2 crossref_primary_10_1016_j_tim_2019_10_001 crossref_primary_10_3389_fimmu_2019_00022 crossref_primary_10_3389_fmicb_2022_966235 crossref_primary_10_1038_s41598_021_83737_5 crossref_primary_10_1111_febs_15756 crossref_primary_10_3390_nu13010276 crossref_primary_10_1016_j_vaccine_2020_04_075 crossref_primary_10_1016_j_coi_2019_07_005 crossref_primary_10_1016_j_vaccine_2023_04_021 crossref_primary_10_3390_vaccines12121354 crossref_primary_10_3390_vaccines7040164 crossref_primary_10_3390_cells11071153 crossref_primary_10_2217_nnm_2022_0082 crossref_primary_10_1111_irv_12729 crossref_primary_10_1111_irv_12726 crossref_primary_10_1177_1934578X231171521 crossref_primary_10_1093_cid_ciad161 crossref_primary_10_1016_j_clim_2020_108593 crossref_primary_10_1016_j_ijregi_2025_100609 crossref_primary_10_1371_journal_pone_0251361 crossref_primary_10_1093_infdis_jiab560 crossref_primary_10_1111_irv_12850 crossref_primary_10_1183_16000617_0106_2024 crossref_primary_10_3390_pathogens12020154 crossref_primary_10_1080_21645515_2021_1883379 crossref_primary_10_55095_CSPediatrie2023_027 crossref_primary_10_1016_j_jconrel_2025_113629 crossref_primary_10_3389_fimmu_2025_1542592 crossref_primary_10_1080_15548627_2020_1812218 crossref_primary_10_1038_s41390_023_02780_2 crossref_primary_10_2147_CEOR_S382495 crossref_primary_10_1177_2049936119865798 crossref_primary_10_1080_14760584_2020_1711053 crossref_primary_10_1038_s41579_019_0149_x crossref_primary_10_1126_scitranslmed_ade6422 crossref_primary_10_3892_ijmm_2020_4596 crossref_primary_10_3389_fimmu_2021_664212 crossref_primary_10_1093_eurjpc_zwae016 crossref_primary_10_1016_j_pharmthera_2020_107712 crossref_primary_10_1080_08998280_2025_2488211 crossref_primary_10_1186_s12879_020_05175_4 crossref_primary_10_1002_jcla_24889 crossref_primary_10_4103_atm_atm_202_24 crossref_primary_10_3390_v13081493 crossref_primary_10_1177_20499361221099447 crossref_primary_10_18553_jmcp_2022_21459 crossref_primary_10_4155_bio_2022_0097 crossref_primary_10_3390_microorganisms13081876 crossref_primary_10_1111_apm_13484 crossref_primary_10_1093_infdis_jiac114 crossref_primary_10_1164_rccm_202005_1660OC crossref_primary_10_1177_20499361221128091 crossref_primary_10_3390_vaccines9111334 crossref_primary_10_1016_j_jim_2021_113054 crossref_primary_10_1093_infdis_jiab023 crossref_primary_10_3389_fcimb_2023_1193113 crossref_primary_10_1093_infdis_jiac110 crossref_primary_10_3390_v13071214 crossref_primary_10_3389_fmicb_2025_1498955 crossref_primary_10_1542_peds_2020_1727 crossref_primary_10_1111_irv_12672 crossref_primary_10_1038_s41598_023_47015_w crossref_primary_10_1016_j_ijid_2023_05_009 crossref_primary_10_1007_s00705_019_04230_z crossref_primary_10_1038_s41541_025_01231_9 crossref_primary_10_1186_s12879_024_08988_9 crossref_primary_10_1016_j_vaccine_2020_07_029 crossref_primary_10_1164_rccm_202006_2154ED crossref_primary_10_1002_adfm_202510925 crossref_primary_10_1164_rccm_201901_0233ED crossref_primary_10_1038_s41541_019_0150_4 crossref_primary_10_1186_s12985_020_01451_6 crossref_primary_10_3389_fimmu_2019_01675 crossref_primary_10_1016_j_vaccine_2021_03_096 crossref_primary_10_1016_j_vacune_2023_03_002 crossref_primary_10_1093_infdis_jiz409 crossref_primary_10_1111_irv_12666 crossref_primary_10_3389_fmicb_2025_1599093 crossref_primary_10_1016_j_vaccine_2019_09_096 crossref_primary_10_1097_ID9_0000000000000003 crossref_primary_10_1093_infdis_jiaa063 crossref_primary_10_1093_ve_vead006 crossref_primary_10_1038_s41541_020_0163_z crossref_primary_10_1093_infdis_jiac481 crossref_primary_10_1177_20499361221112171 crossref_primary_10_3390_v15091914 crossref_primary_10_1038_s41598_019_54240_9 crossref_primary_10_1016_j_molstruc_2023_136565 crossref_primary_10_1093_cid_ciab509 crossref_primary_10_1146_annurev_virology_091919_092720 crossref_primary_10_3390_vaccines10050729 crossref_primary_10_1016_j_ebiom_2022_103891 crossref_primary_10_1016_j_virusres_2024_199421 crossref_primary_10_1038_s41541_020_0200_y crossref_primary_10_3390_microorganisms8122048 crossref_primary_10_1371_journal_ppat_1013312 crossref_primary_10_3389_fimmu_2023_1283120 crossref_primary_10_1016_j_sste_2021_100434 crossref_primary_10_1097_INF_0000000000002494 crossref_primary_10_3389_fcimb_2019_00075 crossref_primary_10_1002_14651858_CD015134_pub2 crossref_primary_10_1016_j_biocel_2024_106588 crossref_primary_10_3389_fimmu_2021_747866 crossref_primary_10_1093_infdis_jiaa034 crossref_primary_10_3389_fimmu_2019_00810 crossref_primary_10_54044_RAMI_2023_01_06 crossref_primary_10_1111_jcmm_18338 crossref_primary_10_1186_s12879_022_07261_1 crossref_primary_10_1016_j_vaccine_2024_126427 crossref_primary_10_1099_jgv_0_001287 crossref_primary_10_1016_j_carbpol_2020_116613 crossref_primary_10_1186_s12985_023_02227_4 crossref_primary_10_3390_nano10061072 crossref_primary_10_3390_jcm8040486 crossref_primary_10_1111_jpc_15232 crossref_primary_10_1177_2049936119871127 crossref_primary_10_1002_iid3_1257 crossref_primary_10_1016_j_vaccine_2023_10_067 crossref_primary_10_3389_fmicb_2019_00873 crossref_primary_10_1093_infdis_jiac228 crossref_primary_10_1111_irv_12639 crossref_primary_10_1093_infdis_jiad436 crossref_primary_10_1016_j_jcv_2020_104506 crossref_primary_10_1111_irv_12885 crossref_primary_10_3390_vaccines7030069 crossref_primary_10_1080_22221751_2023_2192821 crossref_primary_10_1093_infdis_jiad551 crossref_primary_10_1128_aac_01032_22 crossref_primary_10_1038_s41541_022_00487_9 crossref_primary_10_1016_j_ijporl_2019_109833 crossref_primary_10_1016_S0140_6736_22_00623_7 crossref_primary_10_1111_pai_14098 crossref_primary_10_1128_spectrum_02606_22 crossref_primary_10_1186_s13643_019_1251_x crossref_primary_10_1038_s41467_024_47450_x crossref_primary_10_1007_s40121_020_00383_6 crossref_primary_10_1056_NEJMe2205701 crossref_primary_10_1055_s_0042_1758728 crossref_primary_10_2147_PROM_S298736 crossref_primary_10_1016_j_jinf_2021_12_012 crossref_primary_10_1038_s41467_019_09085_1 crossref_primary_10_1016_j_vaccine_2021_06_013 crossref_primary_10_1016_j_vaccine_2019_09_041 crossref_primary_10_1093_infdis_jiad484 crossref_primary_10_1183_16000617_0034_2023 crossref_primary_10_1128_JVI_02217_20 crossref_primary_10_1016_j_epidem_2021_100444 crossref_primary_10_1016_j_anai_2020_03_017 crossref_primary_10_3390_vaccines8040672 crossref_primary_10_1002_ppul_71022 crossref_primary_10_1146_annurev_med_061323_073934 crossref_primary_10_1038_s41541_023_00729_4 crossref_primary_10_3389_fimmu_2020_00717 crossref_primary_10_3390_v12090906 crossref_primary_10_1093_infdis_jiaa424 crossref_primary_10_3201_eid2706_204608 crossref_primary_10_1056_NEJMoa1913556 crossref_primary_10_1002_jmv_25437 crossref_primary_10_3390_vaccines13050528 crossref_primary_10_3389_fimmu_2023_1215323 crossref_primary_10_3390_vaccines7010007 crossref_primary_10_1007_s10405_019_0252_8 crossref_primary_10_1016_S2213_2600_21_00098_9 crossref_primary_10_3390_polym13132141 crossref_primary_10_1016_j_rmr_2023_05_001 crossref_primary_10_1056_NEJMoa2106062 crossref_primary_10_1016_j_chom_2021_12_012 crossref_primary_10_3389_fimmu_2022_938598 crossref_primary_10_3390_v13122478 crossref_primary_10_1097_INF_0000000000002333 crossref_primary_10_1080_21645515_2025_2517931 crossref_primary_10_1093_cid_ciaa730 crossref_primary_10_1016_j_vaccine_2025_127203 crossref_primary_10_1016_j_immuni_2021_03_004 crossref_primary_10_36233_0372_9311_675 crossref_primary_10_1136_thoraxjnl_2018_212212 crossref_primary_10_1371_journal_pcbi_1010360 crossref_primary_10_1093_infdis_jiaa754 crossref_primary_10_1007_s00108_023_01552_8 crossref_primary_10_1016_j_physa_2022_127318 crossref_primary_10_1093_cid_ciz659 crossref_primary_10_7774_cevr_2019_8_1_43 crossref_primary_10_1542_peds_2024_067174 crossref_primary_10_3389_fimmu_2020_611946 crossref_primary_10_1080_21505594_2023_2283897 crossref_primary_10_1093_infdis_jiaa076 crossref_primary_10_1016_j_vaccine_2020_06_034 crossref_primary_10_1126_sciimmunol_aax0644 crossref_primary_10_1016_j_jinf_2020_05_078 crossref_primary_10_1089_vim_2020_0217 crossref_primary_10_1093_cid_ciaa726 crossref_primary_10_1002_ppul_25498 crossref_primary_10_1016_j_jmii_2024_12_010 crossref_primary_10_1093_aje_kwab181 crossref_primary_10_1016_j_jbiosc_2024_05_008 crossref_primary_10_3390_v13061023 crossref_primary_10_3390_children8121144 crossref_primary_10_1080_21645515_2024_2344970 crossref_primary_10_1007_s00431_021_03998_0 crossref_primary_10_1038_s41467_025_61153_x crossref_primary_10_1093_cid_ciab497 crossref_primary_10_1128_JCM_01828_20 crossref_primary_10_3390_vaccines8010015 crossref_primary_10_1183_13993003_02688_2020 crossref_primary_10_3390_vaccines7010023 crossref_primary_10_1093_infdis_jiab613 crossref_primary_10_1134_S0006297921030068 crossref_primary_10_1186_s12879_021_06461_5 crossref_primary_10_1177_25151355241308305 crossref_primary_10_1093_jpids_piad042 crossref_primary_10_3389_fimmu_2019_00566 crossref_primary_10_3390_vaccines9101190 crossref_primary_10_1016_j_ejmech_2024_116561 crossref_primary_10_1097_CM9_0000000000003354 crossref_primary_10_1016_j_imbio_2020_152052 crossref_primary_10_1016_j_virusres_2024_199483 crossref_primary_10_3390_microorganisms12112305 crossref_primary_10_3389_fpubh_2023_1171975 |
| Cites_doi | 10.1128/jcm.24.2.197-202.1986 10.1128/JVI.78.7.3524-3532.2004 10.1093/infdis/jix489 10.1371/journal.ppat.1005859 10.1016/S0140-6736(17)30938-8 10.1006/viro.1997.8734 10.1093/oxfordjournals.aje.a120955 10.1086/429695 10.1093/infdis/jix504 10.1093/infdis/jiw453 10.1093/cid/ciw756 10.1073/pnas.1609449113 10.1016/j.vaccine.2015.08.039 10.1080/21645515.2017.1334026 10.1093/infdis/jix503 10.1164/rccm.201412-2256OC 10.1093/infdis/jiv406 10.1073/pnas.0806244105 10.4161/hv.26038 10.1099/0022-1317-74-7-1445 10.1186/1742-4933-7-14 10.1126/scitranslmed.aac8463 10.1128/JVI.01604-08 10.1126/scitranslmed.aac4241 10.1126/science.1234914 10.1016/S2213-2600(15)00255-6 10.1128/JVI.01625-07 10.1016/j.vaccine.2017.05.045 10.1128/AAC.01285-13 10.1093/cid/cis307 10.1016/j.vaccine.2016.08.086 10.1056/NEJMoa1211917 10.1016/j.vaccine.2015.08.056 10.1016/j.vaccine.2007.08.014 10.1164/rccm.201603-0658OC 10.1186/s12979-017-0090-7 10.1038/srep34108 10.1016/j.vaccine.2013.03.020 10.1371/journal.ppat.1005035 10.1016/j.vaccine.2016.12.048 10.1056/NEJM199805143382002 10.1016/j.vaccine.2016.04.002 10.1093/infdis/jix031 10.1038/nature12442 10.1038/ncomms10224 10.2217/imt.15.11 10.1016/j.vaccine.2014.09.030 10.3389/fimmu.2013.00282 10.1016/S1473-3099(15)00247-9 10.1016/S0140-6736(10)60206-1 10.1126/science.1243283 10.1073/pnas.1309070110 10.1542/peds.102.3.531 10.1016/S2214-109X(17)30344-3 10.1128/JVI.72.7.5707-5716.1998 10.1002/ppul.23570 10.1542/peds.2013-0303 10.1097/CJI.0b013e3181c1f1e9 10.1126/sciimmunol.aaj1879 10.1056/NEJMoa043951 10.1136/thoraxjnl-2012-202182 10.1093/cid/cix740 10.4049/jimmunol.0903452 10.1016/j.coviro.2017.03.012 10.1093/infdis/jis671 10.1016/S1473-3099(15)00266-2 10.1038/ncomms9143 10.1099/0022-1317-68-9-2521 10.1016/j.vaccine.2016.11.054 10.1016/j.vaccine.2017.04.053 10.1001/jama.289.2.179 10.1073/pnas.1522597113 10.4049/jimmunol.1300118 10.1128/AAC.01714-16 10.1371/journal.pone.0186854 10.1126/scitranslmed.aaj1928 10.1016/j.coi.2015.04.005 10.1371/journal.pone.0050852 10.1074/jbc.M604292200 |
| ContentType | Journal Article |
| Copyright | 2018 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Copyright © 2018 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved. COPYRIGHT 2018 Elsevier B.V. Copyright Elsevier Limited Oct 2018 |
| Copyright_xml | – notice: 2018 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. – notice: Copyright © 2018 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved. – notice: COPYRIGHT 2018 Elsevier B.V. – notice: Copyright Elsevier Limited Oct 2018 |
| CorporateAuthor | Respiratory Syncytial Virus Network (ReSViNET) Foundation |
| CorporateAuthor_xml | – name: Respiratory Syncytial Virus Network (ReSViNET) Foundation |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7U9 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AEUYN AFKRA BENPR C1K CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P M7N NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 |
| DOI | 10.1016/S1473-3099(18)30292-5 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Environmental Sciences and Pollution Management ProQuest One Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database ProQuest Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1474-4457 |
| EndPage | e311 |
| ExternalDocumentID | A556022832 29914800 10_1016_S1473_3099_18_30292_5 S1473309918302925 |
| Genre | Journal Article Review |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_PC_17220 – fundername: NIAID NIH HHS grantid: P01 AI112524 – fundername: Medical Research Council grantid: MC_PC_14105 – fundername: Medical Research Council grantid: MR/R502121/1 – fundername: Medical Research Council grantid: MR/R005982/1 – fundername: World Health Organization grantid: 001 |
| GroupedDBID | --- --K --M -RU ..I .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AARKO AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABJNI ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGEKW AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CJTIS CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HF~ HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OD- OO. OZT P-8 P-9 P2P PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSI SSZ T5K TLN UKHRP UV1 WOW XBR Z5R ~HD 3V. AACTN AAYOK ABLVK ABYKQ AFKWA AJBFU AJOXV AMFUW RIG SDF ZA5 9DU AAYXX AFFHD CITATION AFCTW AGCQF AGRNS ALIPV CGR CUY CVF ECM EIF NPM 7QL 7U9 7XB 8FK C1K H94 K9. M7N PKEHL PQEST PQUKI 7X8 PUEGO |
| ID | FETCH-LOGICAL-c591t-9195d20f94a53f309c69eedefa28d7eaea17a60f330fc94f3584e3e9b8129a1b3 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 355 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000445774200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1473-3099 1474-4457 |
| IngestDate | Wed Oct 01 13:11:08 EDT 2025 Mon Oct 06 18:11:32 EDT 2025 Mon Nov 10 02:54:50 EST 2025 Mon Jul 21 06:03:18 EDT 2025 Tue Nov 18 22:33:24 EST 2025 Sat Nov 29 07:06:45 EST 2025 Fri Feb 23 02:32:07 EST 2024 Tue Oct 14 19:31:25 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | Copyright © 2018 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c591t-9195d20f94a53f309c69eedefa28d7eaea17a60f330fc94f3584e3e9b8129a1b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://www.thelancet.com/article/S1473309918302925/pdf |
| PMID | 29914800 |
| PQID | 2154222222 |
| PQPubID | 44001 |
| PageCount | e295 |
| ParticipantIDs | proquest_miscellaneous_2057134581 proquest_journals_2154222222 gale_incontextgauss__A556022832 pubmed_primary_29914800 crossref_primary_10_1016_S1473_3099_18_30292_5 crossref_citationtrail_10_1016_S1473_3099_18_30292_5 elsevier_sciencedirect_doi_10_1016_S1473_3099_18_30292_5 elsevier_clinicalkey_doi_10_1016_S1473_3099_18_30292_5 |
| PublicationCentury | 2000 |
| PublicationDate | October 2018 2018-10-00 20181001 |
| PublicationDateYYYYMMDD | 2018-10-01 |
| PublicationDate_xml | – month: 10 year: 2018 text: October 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: London |
| PublicationTitle | The Lancet infectious diseases |
| PublicationTitleAlternate | Lancet Infect Dis |
| PublicationYear | 2018 |
| Publisher | Elsevier Ltd Elsevier B.V Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier B.V – name: Elsevier Limited |
| References | Sastry, Zhang, Chen (bib79) 2017; 12 Escribano-Romero, Rawling, García-Barreno, Melero (bib41) 2004; 78 Clinicaltrials.gov (bib26) 2018 Schepens, Schotsaert, Saelens (bib45) 2015; 7 Raghunandan, Lu, Zhou (bib62) 2014; 32 Stein, Bont, Zar (bib5) 2017; 52 Wright, Karron, Belshe (bib100) 2007; 25 European Medicines Agency (bib13) 2016 Groothuis, Simoes, Hemming (bib51) 1995; 95 Shi, McAllister, O'Brien (bib1) 2017; 390 McLellan, Chen, Joyce (bib37) 2013; 342 Welliver, Papin, Wolf (bib63) 2014 Kim, Canchola, Brandt (bib9) 1969; 89 Más, Rodriguez, Olmedillas (bib55) 2016; 12 Blanken, Rovers, Molenaar (bib114) 2013; 368 WHO (bib108) 2017 Widjojoatmodjo, Bogaert, Meek (bib72) 2015; 33 Dieussaert (bib74) 2017 ClinicalTrials.gov (bib29) 2017 (bib27) 2017 Mousa, Sauer, Sevy (bib30) 2016; 113 Zhu, McLellan, Kallewaard (bib84) 2017; 9 Bueno, Gonzalez, Cautivo (bib81) 2008; 105 Che, Dormitzer, Gribenko (bib99) 2017 Ngwuta, Chen, Modjarrad (bib20) 2015; 7 Gilman, Castellanos, Chen (bib25) 2016; 1 (bib71) 2015 O'Brien, Chandran, Weatherholtz (bib50) 2015; 15 (bib15) 2017 Chanock, Finberg (bib24) 1957; 66 McLellan, Ray, Peeples (bib38) 2013; 372 Bukreyev, Yang, Fricke (bib42) 2008; 82 McLellan, Chen, Leung (bib21) 2013; 340 Hosken, Plikaytis, Trujillo, Mahmood, Higgins, Participating Laboratories Working Group (bib57) 2017; 35 Smith, Wu, Massare, Liu (bib86) 2012 Krarup, Truan, Furmanova-Hollenstein (bib34) 2015; 6 Corti, Bianchi, Vanzetta (bib54) 2013; 501 Achten, Wu, Bont (bib113) 2017; 215 Céspedes, Rey-Jurado, Espinoza (bib83) 2017; 35 Habibi, Jozwik, Makris (bib11) 2015; 191 (bib77) 2017 Dall'Acqua, Kiener, Wu (bib104) 2006; 281 Thompson, Shay, Weintraub (bib7) 2003; 289 Belshe, Mendelman, Treanor (bib112) 1998; 338 Langley, MacDonald, Weir (bib78) 2017 Graham, Modjarrad, McLellan (bib40) 2015; 35 Collins, Mottet (bib44) 1993; 74 Cowling, Fang, Nishiura (bib111) 2012; 54 Fearns, Peeples, Collins (bib46) 1997; 236 WHO (bib18) 2017 WHO (bib109) 2017 (bib14) 2016 Palavecino, Cespedes, Gomez, Kalergis, Bueno (bib80) 2014; 192 Gilman, Moin, Mas (bib53) 2015; 11 (bib23) 2017 (bib52) 1998; 102 Jordan (bib69) 2016 Langley, Aggarwal, Toma (bib76) 2017; 215 Cusi, Martorelli, Di Genova, Terrosi, Campoccia, Correale (bib93) 2010; 7 Falsey, Hennessey, Formica, Cox, Walsh (bib8) 2005; 352 Karkada, Weir, Quinton (bib97) 2010; 33 Fries, Shinde, Stoddard (bib67) 2017; 14 Triantafilou, Kar, Vakakis, Kotecha, Triantafilou (bib43) 2013; 68 Karron, Buchholz, Collins (bib101) 2013; 372 (bib70) 2017 Killikelly, Kanekiyo, Graham (bib36) 2016; 6 Langley (bib33) 2017; 216 Clinicaltrials.gov (bib88) 2018 Jozwik, Habibi, Paras (bib10) 2015; 6 Glenn, Fries, Smith (bib64) 2015; 33 Mazur, Martinón-Torres, Baraldi (bib22) 2015; 3 Creech, Dekker, Ho (bib94) 2013; 9 Cohen, Walaza, Treurnicht (bib2) 2018; 66 Smith, Raghunandan, Wu (bib61) 2012; 7 Griffin, Khan, Esser (bib85) 2017; 61 Geoghegan, Erviti, Caballero (bib3) 2017; 195 de Bree, Heidema, van Leeuwen (bib92) 2005; 191 Karron, Luongo, Thumar (bib102) 2015; 7 Gilbert (bib90) 2013; 31 Novavax Investor Presentation of Novavax Inc. Investor Presentation of Novavax, Inc at J.P. Morgan Healthcare Conference; San Francisco; Jan 8–11, 2018. Falloon, Ji, Curtis (bib32) 2016; 34 Saville (bib73) 2017 Liljeroos, Krzyzaniak, Helenius, Butcher (bib49) 2013; 110 Glenn, Fries, Thomas (bib66) 2016; 213 Habibi, Chiu (bib60) 2017; 35 Mazur, Bont, Cohen (bib115) 2016; 64 Nair, Nokes, Gessner (bib19) 2010; 375 Hall, Weinberg, Blumkin (bib6) 2013; 132 Levine, Klaiber-Franco, Paradiso (bib39) 1987; 68 Robbie, Criste, Dall'acqua (bib105) 2013; 57 Yamin, Jones, DeVincenzo (bib17) 2016; 113 WHO (bib107) 2017 Glezen, Taber, Frank, Kasel (bib16) 1986; 140 (bib28) 2015 August, Glenn, Kpamegan (bib65) 2017; 35 (bib68) 2017 (bib58) 2018 European Medicines Agency (bib106) 2017 Berkley (bib110) 2017 Murphy, Prince, Walsh (bib56) 1986; 24 Capella, Chaiwatpongsakorn, Gorrell (bib12) 2017; 216 Barouch, Liu, Peter (bib95) 2013; 207 Cautivo, Bueno, Cortes, Wozniak, Riedel, Kalergis (bib82) 2010; 185 Teng, Collins (bib48) 1998; 72 Scheltema, Gentile, Lucion (bib4) 2017; 5 Van Braeckel-Budimir, Haijema, Leenhouts (bib89) 2013; 4 Collins, Graham (bib47) 2008; 82 Liebowitz, Lindbloom, Brandl, Garg, Tucker (bib91) 2015; 15 Taylor (bib59) 2017; 35 Falloon, Yu, Esser (bib31) 2017; 216 ClinicalTrials.gov (bib96) 2018 Rey-Jurado, Soto, Gálvez, Kalergis (bib103) 2017; 13 Graham (bib35) 2017; 23 Steff (bib75) 2015 Shi (10.1016/S1473-3099(18)30292-5_bib1) 2017; 390 Liebowitz (10.1016/S1473-3099(18)30292-5_bib91) 2015; 15 Clinicaltrials.gov (10.1016/S1473-3099(18)30292-5_bib26) Habibi (10.1016/S1473-3099(18)30292-5_bib11) 2015; 191 Falloon (10.1016/S1473-3099(18)30292-5_bib31) 2017; 216 Levine (10.1016/S1473-3099(18)30292-5_bib39) 1987; 68 Fearns (10.1016/S1473-3099(18)30292-5_bib46) 1997; 236 Graham (10.1016/S1473-3099(18)30292-5_bib40) 2015; 35 Thompson (10.1016/S1473-3099(18)30292-5_bib7) 2003; 289 Bukreyev (10.1016/S1473-3099(18)30292-5_bib42) 2008; 82 Corti (10.1016/S1473-3099(18)30292-5_bib54) 2013; 501 Taylor (10.1016/S1473-3099(18)30292-5_bib59) 2017; 35 ClinicalTrials.gov (10.1016/S1473-3099(18)30292-5_bib29) Raghunandan (10.1016/S1473-3099(18)30292-5_bib62) 2014; 32 Fries (10.1016/S1473-3099(18)30292-5_bib67) 2017; 14 Glenn (10.1016/S1473-3099(18)30292-5_bib64) 2015; 33 Creech (10.1016/S1473-3099(18)30292-5_bib94) 2013; 9 Sastry (10.1016/S1473-3099(18)30292-5_bib79) 2017; 12 ClinicalTrials.gov (10.1016/S1473-3099(18)30292-5_bib96) 10.1016/S1473-3099(18)30292-5_bib87 Robbie (10.1016/S1473-3099(18)30292-5_bib105) 2013; 57 Yamin (10.1016/S1473-3099(18)30292-5_bib17) 2016; 113 Bueno (10.1016/S1473-3099(18)30292-5_bib81) 2008; 105 Cusi (10.1016/S1473-3099(18)30292-5_bib93) 2010; 7 Mousa (10.1016/S1473-3099(18)30292-5_bib30) 2016; 113 Hall (10.1016/S1473-3099(18)30292-5_bib6) 2013; 132 Steff (10.1016/S1473-3099(18)30292-5_bib75) 2015 Cautivo (10.1016/S1473-3099(18)30292-5_bib82) 2010; 185 Nair (10.1016/S1473-3099(18)30292-5_bib19) 2010; 375 Schepens (10.1016/S1473-3099(18)30292-5_bib45) 2015; 7 Falloon (10.1016/S1473-3099(18)30292-5_bib32) 2016; 34 McLellan (10.1016/S1473-3099(18)30292-5_bib21) 2013; 340 WHO (10.1016/S1473-3099(18)30292-5_bib109) Berkley (10.1016/S1473-3099(18)30292-5_bib110) Langley (10.1016/S1473-3099(18)30292-5_bib78) 2017 Liljeroos (10.1016/S1473-3099(18)30292-5_bib49) 2013; 110 Mazur (10.1016/S1473-3099(18)30292-5_bib22) 2015; 3 Rey-Jurado (10.1016/S1473-3099(18)30292-5_bib103) 2017; 13 Krarup (10.1016/S1473-3099(18)30292-5_bib34) 2015; 6 European Medicines Agency (10.1016/S1473-3099(18)30292-5_bib106) Karron (10.1016/S1473-3099(18)30292-5_bib101) 2013; 372 Gilman (10.1016/S1473-3099(18)30292-5_bib53) 2015; 11 Triantafilou (10.1016/S1473-3099(18)30292-5_bib43) 2013; 68 Che (10.1016/S1473-3099(18)30292-5_bib99) 2017 Gilman (10.1016/S1473-3099(18)30292-5_bib25) 2016; 1 Teng (10.1016/S1473-3099(18)30292-5_bib48) 1998; 72 Geoghegan (10.1016/S1473-3099(18)30292-5_bib3) 2017; 195 Scheltema (10.1016/S1473-3099(18)30292-5_bib4) 2017; 5 Zhu (10.1016/S1473-3099(18)30292-5_bib84) 2017; 9 Habibi (10.1016/S1473-3099(18)30292-5_bib60) 2017; 35 Hosken (10.1016/S1473-3099(18)30292-5_bib57) 2017; 35 Gilbert (10.1016/S1473-3099(18)30292-5_bib90) 2013; 31 Barouch (10.1016/S1473-3099(18)30292-5_bib95) 2013; 207 de Bree (10.1016/S1473-3099(18)30292-5_bib92) 2005; 191 WHO (10.1016/S1473-3099(18)30292-5_bib107) Chanock (10.1016/S1473-3099(18)30292-5_bib24) 1957; 66 WHO (10.1016/S1473-3099(18)30292-5_bib18) McLellan (10.1016/S1473-3099(18)30292-5_bib38) 2013; 372 McLellan (10.1016/S1473-3099(18)30292-5_bib37) 2013; 342 Mazur (10.1016/S1473-3099(18)30292-5_bib115) 2016; 64 Smith (10.1016/S1473-3099(18)30292-5_bib61) 2012; 7 Belshe (10.1016/S1473-3099(18)30292-5_bib112) 1998; 338 Jozwik (10.1016/S1473-3099(18)30292-5_bib10) 2015; 6 Welliver (10.1016/S1473-3099(18)30292-5_bib63) 2014 Achten (10.1016/S1473-3099(18)30292-5_bib113) 2017; 215 Van Braeckel-Budimir (10.1016/S1473-3099(18)30292-5_bib89) 2013; 4 Karkada (10.1016/S1473-3099(18)30292-5_bib97) 2010; 33 WHO (10.1016/S1473-3099(18)30292-5_bib108) Murphy (10.1016/S1473-3099(18)30292-5_bib56) 1986; 24 Collins (10.1016/S1473-3099(18)30292-5_bib47) 2008; 82 Wright (10.1016/S1473-3099(18)30292-5_bib100) 2007; 25 Collins (10.1016/S1473-3099(18)30292-5_bib44) 1993; 74 (10.1016/S1473-3099(18)30292-5_bib52) 1998; 102 Glenn (10.1016/S1473-3099(18)30292-5_bib66) 2016; 213 Glezen (10.1016/S1473-3099(18)30292-5_bib16) 1986; 140 Cohen (10.1016/S1473-3099(18)30292-5_bib2) 2018; 66 August (10.1016/S1473-3099(18)30292-5_bib65) 2017; 35 Langley (10.1016/S1473-3099(18)30292-5_bib33) 2017; 216 Clinicaltrials.gov (10.1016/S1473-3099(18)30292-5_bib88) Escribano-Romero (10.1016/S1473-3099(18)30292-5_bib41) 2004; 78 Dieussaert (10.1016/S1473-3099(18)30292-5_bib74) 2017 Langley (10.1016/S1473-3099(18)30292-5_bib76) 2017; 215 Kim (10.1016/S1473-3099(18)30292-5_bib9) 1969; 89 Karron (10.1016/S1473-3099(18)30292-5_bib102) 2015; 7 Groothuis (10.1016/S1473-3099(18)30292-5_bib51) 1995; 95 Stein (10.1016/S1473-3099(18)30292-5_bib5) 2017; 52 Más (10.1016/S1473-3099(18)30292-5_bib55) 2016; 12 Ngwuta (10.1016/S1473-3099(18)30292-5_bib20) 2015; 7 Jordan (10.1016/S1473-3099(18)30292-5_bib69) 2016 Blanken (10.1016/S1473-3099(18)30292-5_bib114) 2013; 368 O'Brien (10.1016/S1473-3099(18)30292-5_bib50) 2015; 15 Smith (10.1016/S1473-3099(18)30292-5_bib86) 2012 Saville (10.1016/S1473-3099(18)30292-5_bib73) 2017 Killikelly (10.1016/S1473-3099(18)30292-5_bib36) 2016; 6 Palavecino (10.1016/S1473-3099(18)30292-5_bib80) 2014; 192 Dall'Acqua (10.1016/S1473-3099(18)30292-5_bib104) 2006; 281 Widjojoatmodjo (10.1016/S1473-3099(18)30292-5_bib72) 2015; 33 Stanford (10.1016/S1473-3099(18)30292-5_bib98) 2017 Céspedes (10.1016/S1473-3099(18)30292-5_bib83) 2017; 35 Capella (10.1016/S1473-3099(18)30292-5_bib12) 2017; 216 Graham (10.1016/S1473-3099(18)30292-5_bib35) 2017; 23 Griffin (10.1016/S1473-3099(18)30292-5_bib85) 2017; 61 Cowling (10.1016/S1473-3099(18)30292-5_bib111) 2012; 54 Falsey (10.1016/S1473-3099(18)30292-5_bib8) 2005; 352 European Medicines Agency (10.1016/S1473-3099(18)30292-5_bib13) 30056099 - Lancet Infect Dis. 2018 Sep;18(9):941. doi: 10.1016/S1473-3099(18)30481-X. |
| References_xml | – year: 2017 ident: bib27 article-title: Novavax Positive topline data from phase 2 older adult trial and path forward for RSV F vaccine programs – year: 2018 ident: bib88 article-title: A phase I randomized, observer-blinded, dose-ranging study in healthy subjects 24 toto <72 months of age – volume: 113 start-page: 13239 year: 2016 end-page: 13244 ident: bib17 article-title: Vaccination strategies against respiratory syncytial virus publication-title: Proc Natl Acad Sci USA – volume: 35 start-page: 469 year: 2017 end-page: 480 ident: bib59 article-title: Animal models of respiratory syncytial virus infection publication-title: Vaccine – volume: 64 start-page: 443 year: 2016 end-page: 450 ident: bib115 article-title: Severity of respiratory syncytial virus lower respiratory tract infection with viral coinfection in HIV-uninfected children publication-title: Clin Infect Dis – volume: 7 start-page: e50852 year: 2012 ident: bib61 article-title: Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats publication-title: PLoS One – volume: 12 start-page: e0186854 year: 2017 ident: bib79 article-title: Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus publication-title: PLoS One – volume: 289 start-page: 179 year: 2003 end-page: 186 ident: bib7 article-title: Mortality associated with influenza and respiratory syncytial virus in the United States publication-title: JAMA – year: 2017 ident: bib74 article-title: GSK's Pediatric RSV vaccine program publication-title: Food and Drug Administration (FDA) 150th Meeting of the Vaccines and Related Biological Products Advisory Committee Meeting (VRBPAC); Silver Spring, MD, USA – year: 2017 ident: bib18 article-title: RSV vaccine research and development technical roadmap and WHO Preferred Product Characteristics – volume: 216 start-page: 1362 year: 2017 end-page: 1370 ident: bib31 article-title: An adjuvanted, postfusion F protein–based vaccine did not prevent respiratory syncytial virus illness in older adults publication-title: J Infect Dis – volume: 375 start-page: 1545 year: 2010 end-page: 1555 ident: bib19 article-title: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis publication-title: Lancet – volume: 95 start-page: 463 year: 1995 end-page: 467 ident: bib51 article-title: Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG) publication-title: Pediatrics – year: 2012 ident: bib86 publication-title: Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus – volume: 390 start-page: 946 year: 2017 end-page: 958 ident: bib1 article-title: Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study publication-title: Lancet – volume: 352 start-page: 1749 year: 2005 end-page: 1759 ident: bib8 article-title: Respiratory syncytial virus infection in elderly and high-risk adults publication-title: N Engl J Med – volume: 7 start-page: 312ra175 year: 2015 ident: bib102 article-title: A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children publication-title: Sci Transl Med – volume: 31 start-page: 4241 year: 2013 end-page: 4246 ident: bib90 article-title: Clinical development of modified vaccinia virus Ankara vaccines publication-title: Vaccine – volume: 1 start-page: eaaj1879 year: 2016 ident: bib25 article-title: Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors publication-title: Sci Immunol – year: 2017 ident: bib77 article-title: GlaxoSmithKline Safety, reactogenicity and immunogenicity study of different formulations of GlaxoSmithKline (GSK) biologicals' investigational RSV vaccine (GSK3003891A), in healthy women—Study Results – year: 2017 ident: bib99 publication-title: RSV F protein mutants – volume: 191 start-page: 1040 year: 2015 end-page: 1049 ident: bib11 article-title: Impaired antibody-mediated protection and defective IgA B-Cell memory in experimental infection of adults with respiratory syncytial virus publication-title: Am J Respir Crit Care Med – volume: 74 start-page: 1445 year: 1993 end-page: 1450 ident: bib44 article-title: Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus publication-title: J Gen Virol – volume: 35 start-page: 3082 year: 2017 end-page: 3088 ident: bib57 article-title: A multi-laboratory study of diverse RSV neutralization assays indicates feasibility for harmonization with an international standard publication-title: Vaccine – volume: 15 start-page: 1398 year: 2015 end-page: 1408 ident: bib50 article-title: Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial publication-title: Lancet Infect Dis – reference: Novavax Investor Presentation of Novavax Inc. Investor Presentation of Novavax, Inc at J.P. Morgan Healthcare Conference; San Francisco; Jan 8–11, 2018. – volume: 213 start-page: 411 year: 2016 end-page: 422 ident: bib66 article-title: A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age publication-title: J Infect Dis – volume: 33 start-page: 5406 year: 2015 end-page: 5414 ident: bib72 article-title: Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats publication-title: Vaccine – volume: 5 start-page: e984 year: 2017 end-page: e991 ident: bib4 article-title: Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series publication-title: Lancet Glob Health – volume: 191 start-page: 1710 year: 2005 end-page: 1718 ident: bib92 article-title: Respiratory syncytial virus–specific CD8 + memory T cell responses in elderly persons publication-title: J Infect Dis – volume: 6 start-page: 34108 year: 2016 ident: bib36 article-title: Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus publication-title: Sci Rep – volume: 236 start-page: 188 year: 1997 end-page: 201 ident: bib46 article-title: Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome publication-title: Virology – volume: 216 start-page: 1398 year: 2017 end-page: 1406 ident: bib12 article-title: Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection publication-title: J Infect Dis – volume: 9 start-page: 2548 year: 2013 end-page: 2557 ident: bib94 article-title: Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults publication-title: Hum Vaccin Immunother – volume: 195 start-page: 96 year: 2017 end-page: 103 ident: bib3 article-title: Mortality due to respiratory syncytial virus. burden and risk factors publication-title: Am J Respir Crit Care Med – volume: 11 start-page: e1005035 year: 2015 ident: bib53 article-title: Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein publication-title: PLoS Pathog – year: 2018 ident: bib96 article-title: A study to evaluate the safety and immunogenicity of seasonal influenza vaccine and an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF), with and without co-administration, in adults aged 60 years and older in stable health – volume: 78 start-page: 3524 year: 2004 end-page: 3532 ident: bib41 article-title: The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans publication-title: J Virol – volume: 207 start-page: 248 year: 2013 end-page: 256 ident: bib95 article-title: Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 env vaccine in healthy adults (IPCAVD 001) publication-title: J Infect Dis – volume: 105 start-page: 20822 year: 2008 end-page: 20827 ident: bib81 article-title: Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG publication-title: Proc Natl Acad Sci USA – volume: 215 start-page: 24 year: 2017 end-page: 33 ident: bib76 article-title: A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant publication-title: J Infect Dis – volume: 192 start-page: 214 year: 2014 end-page: 223 ident: bib80 article-title: Immunization with a recombinant Bacillus Calmette-Guerin strain confers protective th1 immunity against the human Metapneumovirus publication-title: J Immunol – volume: 66 start-page: 95 year: 2018 end-page: 103 ident: bib2 article-title: In- and out-of-hospital mortality associated with seasonal and pandemic influenza and respiratory syncytial virus in South Africa, 2009-2013 publication-title: Clin Infect Dis – year: 2017 ident: bib29 article-title: A study to evaluate the efficacy of an RSV F vaccine in older adults – volume: 72 start-page: 5707 year: 1998 end-page: 5716 ident: bib48 article-title: Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles publication-title: J Virol – volume: 372 start-page: 259 year: 2013 end-page: 284 ident: bib101 article-title: Live-attenuated respiratory syncytial virus vaccines publication-title: Curr Top Microbiol Immunol – volume: 7 start-page: 309ra162 year: 2015 ident: bib20 article-title: Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera publication-title: Sci Transl Med – volume: 3 start-page: 888 year: 2015 end-page: 900 ident: bib22 article-title: Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics publication-title: Lancet Respir Med – year: 2017 ident: bib23 article-title: PATH RSV Vaccine and mAb Snapshot—PATH Vaccine Resource Library – year: 2017 ident: bib15 article-title: PRNewswire Regeneron to discontinue development of suptavumab for respiratory syncytial virus. Acquire Media – year: 2015 ident: bib28 article-title: Novavax Novavax announces positive top-line data from phase 2 RSV F-protein vaccine clinical trial in older adults – volume: 15 start-page: 1041 year: 2015 end-page: 1048 ident: bib91 article-title: High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial publication-title: Lancet Infect Dis – volume: 102 start-page: 531 year: 1998 end-page: 537 ident: bib52 article-title: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants publication-title: Pediatrics – volume: 57 start-page: 6147 year: 2013 end-page: 6153 ident: bib105 article-title: A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults publication-title: Antimicrob Agents Chemother – year: 2016 ident: bib69 article-title: A randomized, single-blind, placebo-controlled phase I trial to evaluate the safety, tolerability and immunogenicity of the recombinant MVA-BN ® RSV vaccine in healthy adult subjects publication-title: RSV16, the 10th International Respiratory Syncytial Virus Symposium; Patagonia, Argentina – year: 2018 ident: bib58 article-title: NIBSC Antiserum to respiratory syncytial virus WHO 1st international standard – volume: 68 start-page: 2521 year: 1987 end-page: 2524 ident: bib39 article-title: Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus publication-title: J Gen Virol – year: 2017 ident: bib108 article-title: WHO preferred product characteristics for respiratory syncytial virus (RSV) vaccines. Geneva – volume: 110 start-page: 11133 year: 2013 end-page: 11138 ident: bib49 article-title: Architecture of respiratory syncytial virus revealed by electron cryotomography publication-title: Proc Natl Acad Sci USA – volume: 32 start-page: 6485 year: 2014 end-page: 6492 ident: bib62 article-title: An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization publication-title: Vaccine – volume: 340 start-page: 1113 year: 2013 end-page: 1117 ident: bib21 article-title: Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody publication-title: Science – volume: 215 start-page: 1102 year: 2017 end-page: 1106 ident: bib113 article-title: Interference between respiratory syncytial virus and human rhinovirus infection in infancy publication-title: J Infect Dis – volume: 12 start-page: e1005859 year: 2016 ident: bib55 article-title: Engineering, structure and immunogenicity of the human metapneumovirus f protein in the postfusion conformation publication-title: PLoS Pathog – volume: 33 start-page: 6488 year: 2015 end-page: 6492 ident: bib64 article-title: Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs publication-title: Vaccine – volume: 13 start-page: 2092 year: 2017 end-page: 2097 ident: bib103 article-title: A safe and efficient BCG vectored vaccine to prevent the disease caused by the human respiratory syncytial virus publication-title: Hum Vaccin Immunother – year: 2015 ident: bib75 article-title: Development of RSV vaccines: GlaxoSmithKline publication-title: Vaccine Innovation Conference. Toronto, ON, Canada – year: 2017 ident: bib109 article-title: WHO Global RSV surveillance pilot—objectives – volume: 82 start-page: 2040 year: 2008 end-page: 2055 ident: bib47 article-title: Viral and host factors in human respiratory syncytial virus pathogenesis publication-title: J Virol – volume: 9 start-page: eaaj1928 year: 2017 ident: bib84 article-title: A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants publication-title: Sci Transl Med – volume: 54 start-page: 1778 year: 2012 end-page: 1783 ident: bib111 article-title: Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine publication-title: Clin Infect Dis – volume: 342 start-page: 592 year: 2013 end-page: 598 ident: bib37 article-title: Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus publication-title: Science – volume: 35 start-page: 3749 year: 2017 end-page: 3759 ident: bib65 article-title: A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age publication-title: Vaccine – volume: 6 start-page: 8143 year: 2015 ident: bib34 article-title: A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism publication-title: Nat Commun – volume: 23 start-page: 107 year: 2017 end-page: 112 ident: bib35 article-title: Vaccine development for respiratory syncytial virus publication-title: Curr Opin Virol – volume: 368 start-page: 1791 year: 2013 end-page: 1799 ident: bib114 article-title: Respiratory syncytial virus and recurrent wheeze in healthy preterm infants publication-title: N Engl J Med – year: 2017 ident: bib107 article-title: RSV vaccine research and development technology roadmap: Priority activities for development, testing, licensure and global use of RSV vaccines, with a specific focus on the medical need for young children in low-and middle-income countries. Geneva – volume: 281 start-page: 23514 year: 2006 end-page: 23524 ident: bib104 article-title: Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) publication-title: J Biol Chem – volume: 501 start-page: 439 year: 2013 end-page: 443 ident: bib54 article-title: Cross-neutralization of four paramyxoviruses by a human monoclonal antibody publication-title: Nature – volume: 7 start-page: 203 year: 2015 end-page: 206 ident: bib45 article-title: Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen publication-title: Immunotherapy – volume: 140 start-page: 543 year: 1986 end-page: 546 ident: bib16 article-title: Risk of primary infection and reinfection with respiratory syncytial virus publication-title: Am J Dis Child – volume: 185 start-page: 7633 year: 2010 end-page: 7645 ident: bib82 article-title: Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection publication-title: J Immunol – volume: 34 start-page: 2847 year: 2016 end-page: 2854 ident: bib32 article-title: A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant publication-title: Vaccine – volume: 82 start-page: 12191 year: 2008 end-page: 12204 ident: bib42 article-title: The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes publication-title: J Virol – volume: 89 start-page: 422 year: 1969 end-page: 434 ident: bib9 article-title: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine publication-title: Am J Epidemiol – year: 2017 ident: bib73 article-title: Development of a vaccine for prevention of respiratory syncytial virus (RSV) disease in RSV - naïve infants publication-title: Food and Drug Administration (FDA) 150th Meeting of the Vaccines and Related Biological Products Advisory Committee Meeting (VRBPAC). Silver Spring, MD, USA – year: 2017 ident: bib70 article-title: Bavarian Nordic Bavarian Nordic announces positive data from ongoing phase 2 study investigating a universal RSV vaccine. Company Announcement no .18 – volume: 216 start-page: 1334 year: 2017 end-page: 1336 ident: bib33 article-title: Vaccine prevention of respiratory syncytial virus infection in older adults: the work continues publication-title: J Infect Dis – volume: 35 start-page: 757 year: 2017 end-page: 766 ident: bib83 article-title: A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice publication-title: Vaccine – year: 2017 ident: bib106 article-title: Guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease. EMA/CHMP/257022/2017. London – year: 2017 ident: bib110 article-title: Update from GAVI, the vaccine alliance SAGE meeting – year: 2015 ident: bib71 article-title: Business Wire Vaxart presents positive preclinical data for oral RSV vaccine at RSV Vaccines for the World conference – year: 2017 ident: bib78 publication-title: A RSV vaccine based on the small hydrophobic ectodomain protein presented with a novel lipid-based adjuvant is highly immunogenic and safe in adults. RSV Vaccines for the World Meeting – volume: 7 start-page: 14 year: 2010 ident: bib93 article-title: Age related changes in T cell mediated immune response and effector memory to respiratory syncytial virus (RSV) in healthy subjects publication-title: Immun Ageing – year: 2016 ident: bib13 article-title: Recombinant respiratory syncytial virus vaccine—notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision MEDI7510 – year: 2014 ident: bib63 article-title: Maternal immunization of pregnant baboons with the RSV F Nanoparticle leads to trans-placental transfer of high affinity functional antibodies publication-title: 54th Interscience conference on antimicrobial agents and chemotherapy (ICAAC). Washington, DC, USA – volume: 113 start-page: E6849 year: 2016 end-page: E6858 ident: bib30 article-title: Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein publication-title: Proc Natl Acad Sci USA – volume: 35 start-page: 489 year: 2017 end-page: 495 ident: bib60 article-title: Controlled human infection with RSV: the opportunities of experimental challenge publication-title: Vaccine – volume: 68 start-page: 66 year: 2013 end-page: 75 ident: bib43 article-title: Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation publication-title: Thorax – volume: 6 start-page: 10224 year: 2015 ident: bib10 article-title: RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection publication-title: Nat Commun – volume: 338 start-page: 1405 year: 1998 end-page: 1412 ident: bib112 article-title: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children publication-title: N Engl J Med – volume: 24 start-page: 197 year: 1986 end-page: 202 ident: bib56 article-title: Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine publication-title: J Clin Microbiol – volume: 14 start-page: 8 year: 2017 ident: bib67 article-title: Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults publication-title: Immun Ageing – volume: 52 start-page: 556 year: 2017 end-page: 569 ident: bib5 article-title: Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis publication-title: Pediatr Pulmonol – volume: 33 start-page: 250 year: 2010 end-page: 261 ident: bib97 article-title: A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses publication-title: J Immunother – volume: 132 start-page: e341 year: 2013 end-page: e348 ident: bib6 article-title: Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age publication-title: Pediatrics – volume: 25 start-page: 7372 year: 2007 end-page: 7378 ident: bib100 article-title: The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines publication-title: Vaccine – year: 2018 ident: bib26 article-title: Study to evaluate the efficacy and safety of REGN2222, for the prevention of medically attended RSV (Respiratory Syncytial Virus) infection in preterm infants – volume: 4 start-page: 282 year: 2013 ident: bib89 article-title: Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications publication-title: Front Immunol – volume: 61 start-page: e01714 year: 2017 end-page: e01716 ident: bib85 article-title: Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion f-targeting monoclonal antibody with an extended half-life, in healthy adults publication-title: Antimicrob Agents Chemother – year: 2017 ident: bib68 article-title: Novavax Clinical Stage Pipeline—Novavax – volume: 66 start-page: 291 year: 1957 end-page: 300 ident: bib24 article-title: Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children publication-title: Am J Hyg – volume: 372 start-page: 83 year: 2013 end-page: 104 ident: bib38 article-title: Structure and function of respiratory syncytial virus surface glycoproteins publication-title: Curr Top Microbiol Immunol – volume: 35 start-page: 30 year: 2015 end-page: 38 ident: bib40 article-title: Novel antigens for RSV vaccines publication-title: Curr Opin Immunol – year: 2016 ident: bib14 article-title: Novavax Press Release Novavax announces topline RSV F vaccine data from two clinical trials in older adults – volume: 24 start-page: 197 year: 1986 ident: 10.1016/S1473-3099(18)30292-5_bib56 article-title: Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine publication-title: J Clin Microbiol doi: 10.1128/jcm.24.2.197-202.1986 – volume: 78 start-page: 3524 year: 2004 ident: 10.1016/S1473-3099(18)30292-5_bib41 article-title: The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans publication-title: J Virol doi: 10.1128/JVI.78.7.3524-3532.2004 – volume: 216 start-page: 1398 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib12 article-title: Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection publication-title: J Infect Dis doi: 10.1093/infdis/jix489 – volume: 12 start-page: e1005859 year: 2016 ident: 10.1016/S1473-3099(18)30292-5_bib55 article-title: Engineering, structure and immunogenicity of the human metapneumovirus f protein in the postfusion conformation publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1005859 – volume: 390 start-page: 946 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib1 article-title: Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study publication-title: Lancet doi: 10.1016/S0140-6736(17)30938-8 – volume: 236 start-page: 188 year: 1997 ident: 10.1016/S1473-3099(18)30292-5_bib46 article-title: Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome publication-title: Virology doi: 10.1006/viro.1997.8734 – year: 2012 ident: 10.1016/S1473-3099(18)30292-5_bib86 publication-title: Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus – volume: 89 start-page: 422 year: 1969 ident: 10.1016/S1473-3099(18)30292-5_bib9 article-title: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a120955 – volume: 191 start-page: 1710 year: 2005 ident: 10.1016/S1473-3099(18)30292-5_bib92 article-title: Respiratory syncytial virus–specific CD8 + memory T cell responses in elderly persons publication-title: J Infect Dis doi: 10.1086/429695 – volume: 216 start-page: 1334 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib33 article-title: Vaccine prevention of respiratory syncytial virus infection in older adults: the work continues publication-title: J Infect Dis doi: 10.1093/infdis/jix504 – volume: 215 start-page: 24 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib76 article-title: A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant publication-title: J Infect Dis doi: 10.1093/infdis/jiw453 – volume: 64 start-page: 443 year: 2016 ident: 10.1016/S1473-3099(18)30292-5_bib115 article-title: Severity of respiratory syncytial virus lower respiratory tract infection with viral coinfection in HIV-uninfected children publication-title: Clin Infect Dis doi: 10.1093/cid/ciw756 – volume: 113 start-page: E6849 year: 2016 ident: 10.1016/S1473-3099(18)30292-5_bib30 article-title: Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1609449113 – volume: 33 start-page: 6488 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib64 article-title: Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs publication-title: Vaccine doi: 10.1016/j.vaccine.2015.08.039 – volume: 372 start-page: 259 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib101 article-title: Live-attenuated respiratory syncytial virus vaccines publication-title: Curr Top Microbiol Immunol – volume: 13 start-page: 2092 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib103 article-title: A safe and efficient BCG vectored vaccine to prevent the disease caused by the human respiratory syncytial virus publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2017.1334026 – volume: 216 start-page: 1362 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib31 article-title: An adjuvanted, postfusion F protein–based vaccine did not prevent respiratory syncytial virus illness in older adults publication-title: J Infect Dis doi: 10.1093/infdis/jix503 – ident: 10.1016/S1473-3099(18)30292-5_bib29 – year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib99 publication-title: RSV F protein mutants – volume: 191 start-page: 1040 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib11 article-title: Impaired antibody-mediated protection and defective IgA B-Cell memory in experimental infection of adults with respiratory syncytial virus publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201412-2256OC – volume: 213 start-page: 411 year: 2016 ident: 10.1016/S1473-3099(18)30292-5_bib66 article-title: A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age publication-title: J Infect Dis doi: 10.1093/infdis/jiv406 – volume: 105 start-page: 20822 year: 2008 ident: 10.1016/S1473-3099(18)30292-5_bib81 article-title: Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0806244105 – volume: 66 start-page: 291 year: 1957 ident: 10.1016/S1473-3099(18)30292-5_bib24 article-title: Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children publication-title: Am J Hyg – volume: 9 start-page: 2548 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib94 article-title: Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults publication-title: Hum Vaccin Immunother doi: 10.4161/hv.26038 – volume: 74 start-page: 1445 year: 1993 ident: 10.1016/S1473-3099(18)30292-5_bib44 article-title: Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus publication-title: J Gen Virol doi: 10.1099/0022-1317-74-7-1445 – volume: 7 start-page: 14 year: 2010 ident: 10.1016/S1473-3099(18)30292-5_bib93 article-title: Age related changes in T cell mediated immune response and effector memory to respiratory syncytial virus (RSV) in healthy subjects publication-title: Immun Ageing doi: 10.1186/1742-4933-7-14 – volume: 7 start-page: 312ra175 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib102 article-title: A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aac8463 – ident: 10.1016/S1473-3099(18)30292-5_bib108 – volume: 82 start-page: 12191 year: 2008 ident: 10.1016/S1473-3099(18)30292-5_bib42 article-title: The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes publication-title: J Virol doi: 10.1128/JVI.01604-08 – volume: 7 start-page: 309ra162 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib20 article-title: Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aac4241 – volume: 340 start-page: 1113 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib21 article-title: Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody publication-title: Science doi: 10.1126/science.1234914 – volume: 3 start-page: 888 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib22 article-title: Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(15)00255-6 – volume: 82 start-page: 2040 year: 2008 ident: 10.1016/S1473-3099(18)30292-5_bib47 article-title: Viral and host factors in human respiratory syncytial virus pathogenesis publication-title: J Virol doi: 10.1128/JVI.01625-07 – year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib73 article-title: Development of a vaccine for prevention of respiratory syncytial virus (RSV) disease in RSV - naïve infants publication-title: Food and Drug Administration (FDA) 150th Meeting of the Vaccines and Related Biological Products Advisory Committee Meeting (VRBPAC). Silver Spring, MD, USA – volume: 35 start-page: 3749 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib65 article-title: A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age publication-title: Vaccine doi: 10.1016/j.vaccine.2017.05.045 – volume: 57 start-page: 6147 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib105 article-title: A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01285-13 – volume: 54 start-page: 1778 year: 2012 ident: 10.1016/S1473-3099(18)30292-5_bib111 article-title: Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine publication-title: Clin Infect Dis doi: 10.1093/cid/cis307 – volume: 35 start-page: 489 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib60 article-title: Controlled human infection with RSV: the opportunities of experimental challenge publication-title: Vaccine doi: 10.1016/j.vaccine.2016.08.086 – ident: 10.1016/S1473-3099(18)30292-5_bib110 – volume: 368 start-page: 1791 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib114 article-title: Respiratory syncytial virus and recurrent wheeze in healthy preterm infants publication-title: N Engl J Med doi: 10.1056/NEJMoa1211917 – volume: 33 start-page: 5406 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib72 article-title: Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats publication-title: Vaccine doi: 10.1016/j.vaccine.2015.08.056 – year: 2016 ident: 10.1016/S1473-3099(18)30292-5_bib69 article-title: A randomized, single-blind, placebo-controlled phase I trial to evaluate the safety, tolerability and immunogenicity of the recombinant MVA-BN ® RSV vaccine in healthy adult subjects publication-title: RSV16, the 10th International Respiratory Syncytial Virus Symposium; Patagonia, Argentina – volume: 25 start-page: 7372 year: 2007 ident: 10.1016/S1473-3099(18)30292-5_bib100 article-title: The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2007.08.014 – volume: 95 start-page: 463 year: 1995 ident: 10.1016/S1473-3099(18)30292-5_bib51 article-title: Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG) publication-title: Pediatrics – volume: 195 start-page: 96 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib3 article-title: Mortality due to respiratory syncytial virus. burden and risk factors publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201603-0658OC – volume: 14 start-page: 8 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib67 article-title: Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults publication-title: Immun Ageing doi: 10.1186/s12979-017-0090-7 – volume: 6 start-page: 34108 year: 2016 ident: 10.1016/S1473-3099(18)30292-5_bib36 article-title: Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus publication-title: Sci Rep doi: 10.1038/srep34108 – year: 2014 ident: 10.1016/S1473-3099(18)30292-5_bib63 article-title: Maternal immunization of pregnant baboons with the RSV F Nanoparticle leads to trans-placental transfer of high affinity functional antibodies publication-title: 54th Interscience conference on antimicrobial agents and chemotherapy (ICAAC). Washington, DC, USA – year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib78 – volume: 31 start-page: 4241 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib90 article-title: Clinical development of modified vaccinia virus Ankara vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2013.03.020 – volume: 11 start-page: e1005035 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib53 article-title: Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1005035 – volume: 35 start-page: 757 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib83 article-title: A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice publication-title: Vaccine doi: 10.1016/j.vaccine.2016.12.048 – year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib98 article-title: DepoVax™: A novel delivery formulation for cancer immunotherapy and infectious disease vaccines publication-title: Vaccine Innovation Conference; Montreal, QC, Canada – volume: 338 start-page: 1405 year: 1998 ident: 10.1016/S1473-3099(18)30292-5_bib112 article-title: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children publication-title: N Engl J Med doi: 10.1056/NEJM199805143382002 – year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib74 article-title: GSK's Pediatric RSV vaccine program publication-title: Food and Drug Administration (FDA) 150th Meeting of the Vaccines and Related Biological Products Advisory Committee Meeting (VRBPAC); Silver Spring, MD, USA – volume: 34 start-page: 2847 year: 2016 ident: 10.1016/S1473-3099(18)30292-5_bib32 article-title: A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant publication-title: Vaccine doi: 10.1016/j.vaccine.2016.04.002 – volume: 215 start-page: 1102 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib113 article-title: Interference between respiratory syncytial virus and human rhinovirus infection in infancy publication-title: J Infect Dis doi: 10.1093/infdis/jix031 – volume: 501 start-page: 439 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib54 article-title: Cross-neutralization of four paramyxoviruses by a human monoclonal antibody publication-title: Nature doi: 10.1038/nature12442 – ident: 10.1016/S1473-3099(18)30292-5_bib96 – volume: 6 start-page: 10224 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib10 article-title: RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection publication-title: Nat Commun doi: 10.1038/ncomms10224 – volume: 7 start-page: 203 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib45 article-title: Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen publication-title: Immunotherapy doi: 10.2217/imt.15.11 – volume: 32 start-page: 6485 year: 2014 ident: 10.1016/S1473-3099(18)30292-5_bib62 article-title: An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization publication-title: Vaccine doi: 10.1016/j.vaccine.2014.09.030 – volume: 4 start-page: 282 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib89 article-title: Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications publication-title: Front Immunol doi: 10.3389/fimmu.2013.00282 – ident: 10.1016/S1473-3099(18)30292-5_bib13 – volume: 15 start-page: 1398 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib50 article-title: Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)00247-9 – year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib75 article-title: Development of RSV vaccines: GlaxoSmithKline publication-title: Vaccine Innovation Conference. Toronto, ON, Canada – ident: 10.1016/S1473-3099(18)30292-5_bib18 – volume: 375 start-page: 1545 year: 2010 ident: 10.1016/S1473-3099(18)30292-5_bib19 article-title: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(10)60206-1 – ident: 10.1016/S1473-3099(18)30292-5_bib106 – volume: 342 start-page: 592 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib37 article-title: Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus publication-title: Science doi: 10.1126/science.1243283 – volume: 110 start-page: 11133 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib49 article-title: Architecture of respiratory syncytial virus revealed by electron cryotomography publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1309070110 – ident: 10.1016/S1473-3099(18)30292-5_bib107 – volume: 102 start-page: 531 year: 1998 ident: 10.1016/S1473-3099(18)30292-5_bib52 article-title: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants publication-title: Pediatrics doi: 10.1542/peds.102.3.531 – volume: 5 start-page: e984 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib4 article-title: Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(17)30344-3 – volume: 72 start-page: 5707 year: 1998 ident: 10.1016/S1473-3099(18)30292-5_bib48 article-title: Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles publication-title: J Virol doi: 10.1128/JVI.72.7.5707-5716.1998 – volume: 52 start-page: 556 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib5 article-title: Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis publication-title: Pediatr Pulmonol doi: 10.1002/ppul.23570 – volume: 132 start-page: e341 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib6 article-title: Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age publication-title: Pediatrics doi: 10.1542/peds.2013-0303 – volume: 33 start-page: 250 year: 2010 ident: 10.1016/S1473-3099(18)30292-5_bib97 article-title: A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses publication-title: J Immunother doi: 10.1097/CJI.0b013e3181c1f1e9 – volume: 1 start-page: eaaj1879 year: 2016 ident: 10.1016/S1473-3099(18)30292-5_bib25 article-title: Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors publication-title: Sci Immunol doi: 10.1126/sciimmunol.aaj1879 – volume: 352 start-page: 1749 year: 2005 ident: 10.1016/S1473-3099(18)30292-5_bib8 article-title: Respiratory syncytial virus infection in elderly and high-risk adults publication-title: N Engl J Med doi: 10.1056/NEJMoa043951 – volume: 68 start-page: 66 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib43 article-title: Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation publication-title: Thorax doi: 10.1136/thoraxjnl-2012-202182 – volume: 66 start-page: 95 year: 2018 ident: 10.1016/S1473-3099(18)30292-5_bib2 article-title: In- and out-of-hospital mortality associated with seasonal and pandemic influenza and respiratory syncytial virus in South Africa, 2009-2013 publication-title: Clin Infect Dis doi: 10.1093/cid/cix740 – ident: 10.1016/S1473-3099(18)30292-5_bib87 – volume: 185 start-page: 7633 year: 2010 ident: 10.1016/S1473-3099(18)30292-5_bib82 article-title: Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection publication-title: J Immunol doi: 10.4049/jimmunol.0903452 – volume: 140 start-page: 543 year: 1986 ident: 10.1016/S1473-3099(18)30292-5_bib16 article-title: Risk of primary infection and reinfection with respiratory syncytial virus publication-title: Am J Dis Child – ident: 10.1016/S1473-3099(18)30292-5_bib109 – volume: 23 start-page: 107 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib35 article-title: Vaccine development for respiratory syncytial virus publication-title: Curr Opin Virol doi: 10.1016/j.coviro.2017.03.012 – volume: 372 start-page: 83 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib38 article-title: Structure and function of respiratory syncytial virus surface glycoproteins publication-title: Curr Top Microbiol Immunol – volume: 207 start-page: 248 year: 2013 ident: 10.1016/S1473-3099(18)30292-5_bib95 article-title: Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 env vaccine in healthy adults (IPCAVD 001) publication-title: J Infect Dis doi: 10.1093/infdis/jis671 – volume: 15 start-page: 1041 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib91 article-title: High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)00266-2 – volume: 6 start-page: 8143 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib34 article-title: A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism publication-title: Nat Commun doi: 10.1038/ncomms9143 – volume: 68 start-page: 2521 year: 1987 ident: 10.1016/S1473-3099(18)30292-5_bib39 article-title: Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus publication-title: J Gen Virol doi: 10.1099/0022-1317-68-9-2521 – volume: 35 start-page: 469 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib59 article-title: Animal models of respiratory syncytial virus infection publication-title: Vaccine doi: 10.1016/j.vaccine.2016.11.054 – volume: 35 start-page: 3082 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib57 article-title: A multi-laboratory study of diverse RSV neutralization assays indicates feasibility for harmonization with an international standard publication-title: Vaccine doi: 10.1016/j.vaccine.2017.04.053 – volume: 289 start-page: 179 year: 2003 ident: 10.1016/S1473-3099(18)30292-5_bib7 article-title: Mortality associated with influenza and respiratory syncytial virus in the United States publication-title: JAMA doi: 10.1001/jama.289.2.179 – volume: 113 start-page: 13239 year: 2016 ident: 10.1016/S1473-3099(18)30292-5_bib17 article-title: Vaccination strategies against respiratory syncytial virus publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1522597113 – volume: 192 start-page: 214 year: 2014 ident: 10.1016/S1473-3099(18)30292-5_bib80 article-title: Immunization with a recombinant Bacillus Calmette-Guerin strain confers protective th1 immunity against the human Metapneumovirus publication-title: J Immunol doi: 10.4049/jimmunol.1300118 – ident: 10.1016/S1473-3099(18)30292-5_bib26 – volume: 61 start-page: e01714 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib85 article-title: Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion f-targeting monoclonal antibody with an extended half-life, in healthy adults publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01714-16 – ident: 10.1016/S1473-3099(18)30292-5_bib88 – volume: 12 start-page: e0186854 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib79 article-title: Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus publication-title: PLoS One doi: 10.1371/journal.pone.0186854 – volume: 9 start-page: eaaj1928 year: 2017 ident: 10.1016/S1473-3099(18)30292-5_bib84 article-title: A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaj1928 – volume: 35 start-page: 30 year: 2015 ident: 10.1016/S1473-3099(18)30292-5_bib40 article-title: Novel antigens for RSV vaccines publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2015.04.005 – volume: 7 start-page: e50852 year: 2012 ident: 10.1016/S1473-3099(18)30292-5_bib61 article-title: Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats publication-title: PLoS One doi: 10.1371/journal.pone.0050852 – volume: 281 start-page: 23514 year: 2006 ident: 10.1016/S1473-3099(18)30292-5_bib104 article-title: Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) publication-title: J Biol Chem doi: 10.1074/jbc.M604292200 – reference: 30056099 - Lancet Infect Dis. 2018 Sep;18(9):941. doi: 10.1016/S1473-3099(18)30481-X. |
| SSID | ssj0017104 |
| Score | 2.6777475 |
| SecondaryResourceType | review_article |
| Snippet | The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65... Summary The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults... |
| SourceID | proquest gale pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e295 |
| SubjectTerms | Adults Antibodies, Monoclonal - immunology Antibodies, Viral - immunology Antigens Candidates Children Clinical trials COVID-19 vaccines Disease prevention Global Health Glycoproteins Humans Immunoglobulins Immunology Infants Infections Infectious diseases Medical research Monoclonal antibodies Mutation Nanoparticles Older people Proteins Respiratory syncytial virus Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines - immunology Vaccine development Vaccines Viruses World Health Organization |
| Title | The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1473309918302925 https://dx.doi.org/10.1016/S1473-3099(18)30292-5 https://www.ncbi.nlm.nih.gov/pubmed/29914800 https://www.proquest.com/docview/2154222222 https://www.proquest.com/docview/2057134581 |
| Volume | 18 |
| WOSCitedRecordID | wos000445774200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-4457 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: 7X7 dateStart: 20010801 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-4457 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: 7RV dateStart: 20010801 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-4457 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: BENPR dateStart: 20010801 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-4457 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: 8C1 dateStart: 20010801 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB-0FSmIH_UrWusKPuhDbDa7SXZ9kVpafPEo9YN7WzabXSkcufZyd9D_3pl8HRS0gvewD3eZkMv8MvPLzM4MwNtUc1uK1MWp9TKWVSJiHUQahwzJs6xUlZehHTZRTCZqOtWnfcCt6bdVDjaxNdTV3FGM_ABdE0Ur8PPp4jKmqVGUXe1HaNyGbU7cGPFcnP0cswjoPdussixELJAKbSp4Dr6NX77j6r1IUo3vZH_yTdeN9TUK2rqikwf_-ycewv2ehLLDDjWP4Javd-Hu1z7Nvgv3umAe62qUHkNAMLHFJinPmiu0yWgbZmx9vlg1bG0dSbK2cJi2VH1kMzShiGhG9SsMWSZrBx1dISAZHsTwwhFh6DeZo8Iaijs0T-DHyfH3oy9xP6AhdpnmSzSUOqvSJGhpMxHwZrpco8_1waaqKrz1lhc2T4IQSXBaBoFsxwuvS2QV2vJSPIWtel7758Cor15W6tJxr2VelarUlPHlQWkkfNxFIAfVGNd3L6chGjMzblMjjRrSqOHKtBo1WQQfRrGLrn3HTQL5oHcz1KaiNTXoYG4SVKNgT146UvIvoq8JYIbacdS03-eXXTWNMYcZ0lFqT5RGsDfgyfQ2pjEbMEXwZvwZdUcpH1v7-QqPQTrOhcwUj-BZh9nxPiARwXfhJHnx95O_hB0kiV0PYL4HW8vFyr-CO269PG8W--0DR-u0aFeFqzri-7D9-XhyevYbDxIv7g |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1baxNBFD7UKiqIl3pbrXYEBX1YuzOztxFEilpa2gbBFvI2zs7OSCEkNZtE8qf8jZ6zt0BB60sfzGOyZyCz55zvOzPnAvBSKG4KKWwojIvDuIxkqLwUoU-QPMdlXqaFr4dNZINBPhyqL2vwq6uFobTKzifWjrqcWDoj30ZootMK_Hw4-xHS1Ci6Xe1GaDRqceCWPzFkq97vf8L3-0qI3c_HH_fCdqpAaBPFZ2jdKilF5FVsEullpGyqECicNyIvM2ec4ZlJI4-Bvrcq9hIh2kmnCoRCZXghcd0rcBX9eEbBXjbsAzyOaF3fYseZDHFhtaoY2v7af_ma529kJBTGgH_CwvPgcI7y1tC3e-d_27S7cLsl2WynsYp7sObGG3D9qE0j2IBbzWEla2qw7oNHY2HTVdIBq5aIOej7RmxxOp1XbGEsSbK6MJpSxt6xEUIEWiyj-hyGLJrVg5yWaHAMH2K4UWhByAuYpcIhOlepHsDJpfzrh7A-nozdY2DUNzApVGG5U3FaFnmh6Eab-1whoeU2gLhTBW3b7uw0JGSk-zQ80iBNGqR5rmsN0kkAb3uxs6Y9yUUCaadnuqu9RbTQCKAXCea9YEvOGtL1L6JbpNCa2o2MKZ_pu5lXldY7CdJtar8kAtjs9Fe3PrTSK-UN4EX_M747utIyYzeZ4zMYbnAZJzkP4FFjI_0-INHCWD-Knvx98S24sXd8dKgP9wcHT-EmEuKm3zHfhPXZdO6ewTW7mJ1W0-e1sTP4dtmG8hsD74l8 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1baxQxFD7UKkUQL_U2Wm0EBX0YdzKZSyKIlNbFUl0KKvQtZjKJFJbdurO7sn_NX-c5c1soaH3pg_M4MycwmXPyfSc5F4DnseKmELENY-OSMCkjESov4tCnSJ6TUpZZ4etmE_loJE9O1PEG_OpyYSisslsT64W6nFraIx8gNNFuBV4D34ZFHB8M3539CKmDFJ20du00GhU5cquf6L5Vbw8P8F-_iOPh-y_7H8K2w0BoU8XnaOkqLePIq8SkwotI2UwhaDhvYlnmzjjDc5NFHp1-b1XiBcK1E04VCIvK8ELguFfgai4yQY6f3O_DSzgid32ineQixIHVOnto8Lm_-ZLLVyKKFfqDf8LF80Bxjv7WMDi89T9P4G242ZJvttdYyx3YcJNt2PrUhhdsw41mE5M1uVl3waMRsdk6GIFVK8QiXBPHbHk6W1RsaSxJsjphmkLJ3rAxQgdaMqO8HYbsmtUNnlZoiAxfYjhpaFnIF5ilhCLab6nuwddL-er7sDmZTtxDYFRPMC1UYblTSVYWslB00s29VEh0uQ0g6dRC27ZqOzUPGes-PI-0SZM2aS51rU06DeB1L3bWlC25SCDrdE53ObmIIhqB9SJB2Qu2pK0hY_8iukvKrakMyYT08btZVJXWeynScCrLFAew0-mybtfWSq8VOYBn_WP8d3TUZSZuusB30A3hIkklD-BBYy_9PCAB4wn6SY_-PvgubKF96I-Ho6PHcB15clMGme_A5ny2cE_gml3OT6vZ09ruGXy7bDv5Dbl7kgM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+respiratory+syncytial+virus+vaccine+landscape%3A+lessons+from+the+graveyard+and+promising+candidates&rft.jtitle=The+Lancet+infectious+diseases&rft.au=Mazur%2C+Natalie+I&rft.au=Higgins%2C+Deborah&rft.au=Nunes%2C+Marta+C&rft.au=Melero%2C+Jos%C3%A9+A&rft.date=2018-10-01&rft.eissn=1474-4457&rft.volume=18&rft.issue=10&rft.spage=e295&rft_id=info:doi/10.1016%2FS1473-3099%2818%2930292-5&rft_id=info%3Apmid%2F29914800&rft.externalDocID=29914800 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-3099&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-3099&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-3099&client=summon |